Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP3A4 | P08684 | 1/20 | 0.40 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.40 |
| ▸ | CNR2 | P34972 | 1/20 | 0.38 |
| ▸ | HTT | P42858 | 2/20 | 0.36 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.35 |
| ▸ | CA12 | O43570 | 1/20 | 0.35 |
| ▸ | CA1 | P00915 | 1/20 | 0.35 |
| ▸ | CA2 | P00918 | 1/20 | 0.35 |
| ▸ | CA9 | Q16790 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8283032 | 1.00 | CYP3A4 (0.40) | CYP3A4CYP2D6CNR2HTTCYP1A2 | |
| SCHEMBL2737876 | 1.00 | CYP3A4 (0.40) | CYP3A4CYP2D6CNR2HTTCYP1A2 | |
| SCHEMBL21515942 | 0.98 | HTT (0.39) | CYP3A4CYP2D6CNR2HTTCYP1A2 | |
| SCHEMBL890138 | 0.93 | — | — | |
| SCHEMBL412333 | 0.93 | — | — | |
| SCHEMBL8291028 | 0.93 | — | — | |
| SCHEMBL28845774 | 0.84 | CYP3A4 (0.41) | CYP3A4CYP2D6CNR2CYP1A2CA12 | |
| SCHEMBL7800989 | 0.83 | — | — | |
| SCHEMBL8291026 | 0.83 | — | — | |
| SCHEMBL58093 | 0.82 | ACE (0.42) | CYP3A4CYP2D6CNR2HTTALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 92 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2023142600-A1 | AMINO LIPID, PREPARATION METHOD THEREFOR, AND USE THEREOF | 深圳虹信生物科技有限公司 | 2023-08-03 | — | — | WO | disclosed |
| US-20220332687-A1 | HETEROARYL COMPOUNDS AND USES THEREOF | SANOFI (FR) | 2022-10-20 | — | — | US | disclosed |
| EP-3943087-A1 | HETEROARYL COMPOUNDS AND USES THEREOF | Celgene CAR LLC (BM) | 2022-01-26 | — | — | EP | disclosed |
| EP-2968337-B1 | HETEROARYL COMPOUNDS AND USES THEREOF | CELGENE CAR LLC (BM) | 2021-07-21 | — | — | EP | disclosed |
| WO-2021067405-A1 | NEUROPROTECTIVE COMPOUNDS AND METHODS OF USE THEREOF | THE JOHNS HOPKINS UNIVERSITY (US) | 2021-04-08 | — | — | WO | disclosed |
| US-10000535-B2 | Template-fixed peptidomimetics | POLYPHOR LTD. (CH) | 2018-06-19 | — | — | US | disclosed |
| US-9981976-B2 | Piperidine substituted pyrazolo[1,5-A]pyrimidine derivatives with inhibitory activity on the replication of the respiratory syncytial virus (RSV) | JANSSEN SCIENCES IRELAND UC (IE) | 2018-05-29 | — | — | US | disclosed |
| US-20170349591-A1 | PIPERIDINE SUBSTITUTED PYRAZOLO[1,5-A]PYRIMIDINE DERIVATIVES WITH INHIBITORY ACTIVITY ON THE REPLICATION OF THE RESPIRATORY SYNCYTIAL VIRUS (RSV) | JANSSEN INFECTIOUS DISEASES BVBA (BE) | 2017-12-07 | — | — | US | disclosed |
| US-9822147-B2 | Methods of treating ophthalmic diseases using NPR-B agonists | SHIRE ORPHAN THERAPIES GMBH (DE) | 2017-11-21 | — | — | US | disclosed |
| US-20170298097-A1 | Peptide Derivatives and Uses Thereof | NOSOPHARM (FR) | 2017-10-19 | — | — | US | disclosed |
| EP-1816136-A1 | GPR7-SELECTIVE LIGAND AND USE THEREOF | BANYU PHARMACEUTICAL CO., LTD. (JP) | 2007-08-08 | — | — | EP | disclosed |
| US-20070179126-A1 | 2-carbamide-4-phenylthiazole derivatives, preparation thereof and therapeutic use thereof | SANOFI-AVENTIS (FR) | 2007-08-02 | — | — | US | disclosed |
| US-20070179126-A1 | 2-carbamide-4-phenylthiazole derivatives, preparation thereof and therapeutic use thereof | SANOFI-AVENTIS (FR) | 2007-08-02 | — | — | US | disclosed |
| US-20070161789-A1 | Inhibitors of serine proteases, particularly HCV NS3-NS4A protease | VERTEX PHARMACEUTICALS INCORPORATED | 2007-07-12 | — | — | US | disclosed |
| US-20070129364-A1 | Pyrrolopyridine kinase inhibiting compounds | OSI PHARMACEUTICALS, INC. | 2007-06-07 | — | — | US | disclosed |
| US-20070129364-A1 | Pyrrolopyridine kinase inhibiting compounds | OSI PHARMACEUTICALS, INC. | 2007-06-07 | — | — | US | disclosed |
| US-7208600-B2 | Inhibitors of serine proteases, particularly HCV NS3-NS4A proteases | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2007-04-24 | — | — | US | disclosed |
| US-20070037834-A1 | Anti-inflammatory; cellular infiltration inhibition modulating activity on thymus and activation-regulated chemokine and macrophage-derived chemokine functions; inhibitory activities against binding of TARC and MDC to T cells; allergic disease, autoimmune disease, transplant, graft rejection | KYOWA HAKKO KIRIN CO., LTD. (JP) | 2007-02-15 | — | — | US | disclosed |
| US-20070004642-A1 | Oxadiazole derivatives and drugs containing these derivatives as the active ingredient | ONO PHARMACEUTICAL CO., LTD. | 2007-01-04 | — | — | US | disclosed |
| US-20070004642-A1 | Oxadiazole derivatives and drugs containing these derivatives as the active ingredient | ONO PHARMACEUTICAL CO., LTD. | 2007-01-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220332687-A1 | HETEROARYL COMPOUNDS AND USES THEREOF | ABCG2, CYP3A43, CYP3A5 | CYP3A4 6/4885CYP2D6 10/4885CNR2 238/4885 |
| US-20170349591-A1 | PIPERIDINE SUBSTITUTED PYRAZOLO[1,5-A]PYRIMIDINE DERIVATIVES WITH INHIBITORY ACTIVITY ON THE REPLICATION OF THE RESPIRATORY SYNCYTIAL VIRUS (RSV) | ZC3HAV1, RRP15, PIR | CYP3A4 1383/4885CYP2D6 3005/4885CNR2 3839/4885 |
| US-20070161789-A1 | Inhibitors of serine proteases, particularly HCV NS3-NS4A protease | PRSS1, SERPINB1, SPINT2 | CYP3A4 197/4885CYP2D6 1038/4885CNR2 4429/4885 |
| US-20070004642-A1 | Oxadiazole derivatives and drugs containing these derivatives as the active ingredient | ACIN1, CYCS, CASP7 | CYP3A4 1491/4885CYP2D6 3507/4885CNR2 839/4885 |
| US-10000535-B2 | Template-fixed peptidomimetics | CCR10, CXCR3, CCR5 | CYP3A4 4358/4885CYP2D6 4473/4885CNR2 455/4885 |
| US-20070179126-A1 | 2-carbamide-4-phenylthiazole derivatives, preparation thereof and therapeutic use thereof | UGT2B7, PKD2, CYP2C19 | CYP3A4 9/4885CYP2D6 34/4885CNR2 242/4885 |
| US-20070129364-A1 | Pyrrolopyridine kinase inhibiting compounds | BMX, ERBB2, FRK | CYP3A4 4570/4885CYP2D6 4555/4885CNR2 2809/4885 |
| US-20170298097-A1 | Peptide Derivatives and Uses Thereof | VIP, IAPP, NGLY1 | CYP3A4 4784/4885CYP2D6 4742/4885CNR2 4436/4885 |
| US-20070037834-A1 | Anti-inflammatory; cellular infiltration inhibition modulating activity on thymus and activation-regulated chemokine and macrophage-derived chemokine functions; inhibitory activities against binding of TARC and MDC to T cells; allergic disease, autoimmune disease, transplant, graft rejection | CX3CR1, CCL5, CCRL2 | CYP3A4 3835/4885CYP2D6 4256/4885CNR2 2558/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.